AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1098396
Drug: spironolactone, 100
RxNorm normalized name: Spironolactone, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone, 100 mg/day
Trial: 30717797
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks (1 L‐mn subgroup)
Trial: 30717797
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks (2 L subgroup)
Trial: 28911141
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon administration
Trial: 28911141
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro glucagon treatment
Trial: 26285330
Drug: Balneo- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneo- and peloid therapy using sulfide-containing siltypeloids
Trial: 23638898
Drug: Dosage-continued group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage-continued group (n=14)
Trial: 17999271
Drug: Individual cognitive-behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive-behaviour therapy (ICBT)
Trial: 17999271
Drug: Group cognitive-behaviour
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behaviour therapy (GCBT)
Trial: 6990861
Drug: Cimetidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.0 g daily)
Trial: 2923963
Drug: Ranitidine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (1.2 g daily)
Trial: 22781020
Drug: G‐WWB (white
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐WWB (white wheat bread enriched with guar gum)
Trial: 20656965
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation therapy
Trial: 17336254
Drug: General therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapies for MDS
Trial: 10334256
Drug: Intranasal 17
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17 beta-oestradiol (S21400) 100 microg, 200 microg, 300 microg, or 400 microg
Trial: 10334256
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol valerate 1 mg or 2 mg
Trial: 10334256
Drug: Intranasal 17
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17 beta-oestradiol (S21400)
Trial: 28045958
Drug: rhEGF (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEGF (50 microg/mL)
Trial: 20868384
Drug: Basic fibroblast
RxNorm normalized name: Basic Fibroblast Growth Factor
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic fibroblast growth factor (bFGF) spray daily
Trial: 7772359
Drug: lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 1.5 mg/kg
Trial: 17358099
Drug: dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextrose 5% 5 mL (control)
Trial: 15848532
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (stopped steroids)
Trial: 15848532
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (continued steroids)
Trial: 11981384
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (60 mW, transmeatal, once a week for 6 minutes, 4 times over 4 weeks)
Trial: 11981384
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment (transmeatal, once a week for 6 minutes, 4 times over 4 weeks)
Trial: 20561878
Drug: Aspirin (88.2%‐85.7%)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (88.2%‐85.7%)
Trial: 20561878
Drug: Statins or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins or cholesterol‐lowering drugs (88.6%‐87%)
Trial: 20561878
Drug: Beta-blockers (68%‐55.6%)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (68%‐55.6%)
Trial: 19231245
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg intravenously during anesthetic induction)
Trial: 15883757
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg and 1 mg)
Trial: 15883757
Drug: Propafenone (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (70 mg and 70 mg)
Trial: 9618751
Drug: Supraphysiological GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological GH treatment (3 IU/m2)
Trial: 9618751
Drug: Physiological GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological GH treatment (1 IU/m2 or 2 IU/m2)
Trial: 2728827
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil 0.1 mg.kg‐1
Trial: 2728827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (thiamylal 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1)
Trial: 2728827
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil 0.1 mg.kg‐1 (hypertensive patients)
Trial: 848533
Drug: Ritodrine in
RxNorm normalized name: ritodrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine in Hartmann's solution
Trial: 31060104
Drug: Violet-almond oil
RxNorm normalized name: Almond Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Violet-almond oil (intranasal, 2 drops three times a day for one month)
Trial: 31060104
Drug: Almond oil
RxNorm normalized name: Almond Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond oil (intranasal, 2 drops three times a day for one month)
Trial: 31060104
Drug: Placebo (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1% w/v hydroxypropyl methylcellulose solution, intranasal, 2 drops three times a day for one month)
Trial: 24672937
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (Control group)
Trial: 12392348
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carbamazepine and lithium
Trial: 12392348
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of valproate and olanzapine
Trial: 25323541
Drug: Gp‐02 (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gp‐02 (test formulation)
Trial: 20303417
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg, twice daily)
Trial: 17403087
Drug: Enoxaparin or
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin or unfractionated heparin
Trial: 9780529
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy instrument
Trial: 26039911
Drug: Supragingival therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supragingival therapy group (ST, n = 12) received supragingival scaling
Trial: 26039911
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy group (IT, n = 12) underwent supra- and subgingival scaling, as well as root planing
Trial: 26039911
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received professional oral hygiene instructions every month
Trial: 12626983
Drug: Naloxone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (8 mg four times daily via gastric tube)
Trial: 12626983
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four times daily via gastric tube)
Trial: 10827889
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy guided by a computer or by a therapist
Trial: 9209989
Drug: 0.1 cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 cc unpreserved lidocaine 1%
Trial: 9209989
Drug: 0.1 cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 cc balanced salt solution (BSS)
Trial: 9209989
Drug: 0.5 cc
RxNorm normalized name: SureComfort Pen 30g, 0.5 cc, 5/16 inches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 cc unpreserved lidocaine 1%
Trial: 2459788
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG therapy for superficial bladder cancer
Trial: 2459788
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics for urinary tract infections
Trial: 29424805
Drug: Blonanserin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blonanserin (8 mg) with alcohol (1 mL/kg)
Trial: 29424805
Drug: Blonanserin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blonanserin (8 mg) with water
Trial: 19712983
Drug: rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20mg once daily
Trial: 12489066
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of voglibose plus a SU compound (glibenclamide or gliclazide)
Trial: 12489066
Drug: SU drug
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU drug alone
Trial: 9809728
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (observation group, 46 patients)
Trial: 7895348
Drug: Accelerated tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated tissue plasminogen activator (TPA) with intravenous heparin
Trial: 7895348
Drug: Streptokinase plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase plus TPA with intravenous heparin
Trial: 2793316
Drug: No intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intraocular drug (Control)
Trial: 330288
Drug: Diclofenac (Voltaren)
RxNorm normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac (Voltaren) 100 mg twice daily
Trial: 6794075
Drug: Doxepin 100
RxNorm normalized name: doxepin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 100 mg
Trial: 30897095
Drug: Improved infant
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved infant and young child feeding (IYCF) - 20 g of small-quantity lipid-based nutrient supplement per day from age 6 to 18 months plus complementary feeding counseling
Trial: 29030692
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (IVBe)
Trial: 29030692
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab with subtenon triamcinolone injection (IVBe + STTA)
Trial: 24981150
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (LD-COC)
Trial: 21415280
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT)
Trial: 2630378
Drug: self blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self blood glucose monitoring, twice every other day
Trial: 2630378
Drug: self-urine glucose
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-urine glucose monitoring, twice every other day
Trial: 798128
Drug: L-dopa +
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa + G 31.406
Trial: 798128
Drug: L-dopa +
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa + chl. amantadine
Trial: 798128
Drug: L-dopa +
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa + placebo
Trial: 30626548
Drug: Bilateral double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral double suspension sutures (DSS)
Trial: 30626548
Drug: Bilateral single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral single palatal suspension sutures (SSS)
Trial: 28671093
Drug: TCM pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM pulmonary rehabilitation therapy
Trial: 21540202
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for fatigue self-management, comprising six weekly 2-hour sessions and a consolidation session at week 14.
Trial: 21540202
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for fatigue self-management.
Trial: 16718764
Drug: Ecabet sodium
RxNorm normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecabet sodium (1.5 g twice a day)
Trial: 16718764
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg twice a day)
Trial: 17427
Drug: Fazadinium 1
RxNorm normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium 1 mg/kg
Trial: 15467
Drug: Fazadinium 1-25
RxNorm normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium 1-25 mg/kg
Trial: 15467
Drug: Alcuronium 0-32
RxNorm normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0-32 mg/kg
Trial: 25555887
Drug: Buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 days
Trial: 25555887
Drug: Buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 28 days
Trial: 25555887
Drug: Buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 or 28 days
Trial: 21975470
Drug: General postoperation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General postoperation therapy (Group A)
Trial: 17873305
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (30 mg/m2), epirubicin (30 mg/m2), and carboplatin (AUC 2) with filgrastim support
Trial: 11518846
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment withdrawal (group A1)
Trial: 11518846
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment withdrawal (group A2)
Trial: 8240556
Drug: Actidose Aqua
RxNorm normalized name: ACTIVATED CHARCOAL 208 mg in 1 mL ORAL SUSPENSION [ACTIDOSE AQUA]
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actidose Aqua AC (1,500 m2/g)
Trial: 8240556
Drug: Norit A
RxNorm normalized name: Norit A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norit A Supra AC (2,000 m2/g)
Trial: 8240556
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase (no AC administered)
Trial: 29357358
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention programme (cognitive therapy, relaxation therapy, emotional support)
Trial: 27624471
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ferroquine
Trial: 23954043
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of health marks and traffic light colour-coding
Trial: 14755115
Drug: Formulation I
RxNorm normalized name: Recombivax HB, Hepatitis B Vaccine (Recombinant) Pediatric/Adolescent Formulation Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation I of ramipril (5 mg)
Trial: 14755115
Drug: Formulation II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation II of ramipril (5 mg)
Trial: 14755115
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of ramipril (5 mg)
Trial: 10864982
Drug: SC G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC G‐CSF at 600 microg and PO dexamethasone at 8 mg
Trial: 10864982
Drug: SC G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC G‐CSF at 450 microg and PO dexamethasone at 8 mg
Trial: 10864982
Drug: SC G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC G‐CSF at 450 microg and PO dexamethasone at 12 mg
Trial: 10864982
Drug: SC G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC G‐CSF at 450 microg
Trial: 10864982
Drug: PO dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO dexamethasone at 12 mg
Trial: 1412655
Drug: Ivermectin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (high doses)
Trial: 4015937
Drug: Chlormethiazole infusion
RxNorm normalized name: chlormethiazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole infusion 10 ml min‐1 over 16 (+/‐ 6) min
Trial: 4015937
Drug: Diazepam loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam loading dose of 20 (+/‐ 15) mg at a rate of 1 mg min‐1
Trial: 30206618
Drug: Plant sterol-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-enriched beverage (2 g of PS added)
Trial: 14668709
Drug: Low-osmolar agents
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-osmolar agents
Trial: 10999872
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 microg and dry powder budesonide 100 microg twice daily
Trial: 10999872
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and dry powder budesonide 200 microg twice daily
Trial: 8771064
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injection around one eye
Trial: 8771064
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injection around the other eye (Control)
Trial: 6366150
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) regimen
Trial: 6366150
Drug: Regular follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular follow-up without primary adjuvant chemotherapy
Trial: 27129008
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 1%
Trial: 27129008
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 2%
Trial: 17652452
Drug: Sublingual 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual 400 microg misoprostol and 100 mg diclofenac
Trial: 6308996
Drug: Locust bean
RxNorm normalized name: Locust Bean Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locust bean gum (LBG) food products (8 to 30 g/day)
Trial: 26562708
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g)
Trial: 26562708
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 g corn starch maltodextrin)